Identification of Immune Subtypes of Lung Squamous Cell Carcinoma by Integrative Genome-Scale Analysis
-
Published:2022-02-02
Issue:
Volume:11
Page:
-
ISSN:2234-943X
-
Container-title:Frontiers in Oncology
-
language:
-
Short-container-title:Front. Oncol.
Author:
Yin Liyuan,Zhang Wen,Pu Dan,Zhai Xiaoqian,Lin Yiyun,Wu Qiang,Chang Tangel,Hu Jia,Li Yan,Zhou Qinghua
Abstract
BackgroundCharacterization of the tumor microenvironment is helpful to understand the tumor immune environment of lung cancer and help predict the prognosis.MethodsFirst, immune subtypes were identified by consensus subtype among lung squamous carcinoma (LUSC) patients. Immune cell infiltration was evaluated by CIBERSORT and ESTIMATE analyses. Then, based on differentially expressed genes (DEGs) identified, a risk score model was constructed. Finally, gene FPR1 was validated by using YTMLC-90.FindingsLUSC samples were divided into four heterogeneous immune subtypes, with significantly different prognoses with subtype 4 having the poorest overall survival (OS). The immune infiltration score showed that subtype 4 was characterized as immune enriched and fibrotic, while subtype 3 was tumor enriched. DEG analysis showed that upregulated genes in subtype 4 were enriched of neutrophil and exhausted T cell-related biological processes. Based on a univariate Cox regression model, prognostic 7 immune-related genes were combined to construct a risk score model and able to predict OS rates in the validation datasets. Wound healing and transwell assay were conducted to evaluate the invasion property after activating the gene FPR1.InterpretationThe analysis of tumor immune microenvironments among LUSC subtypes may provide new insights into the strategy of immunotherapy.
Funder
West China Hospital, Sichuan University
Publisher
Frontiers Media SA
Subject
Cancer Research,Oncology
Reference35 articles.
1. Cancer Statistics, 2020;Siegel;CA: Cancer J Clin,2020
2. Diagnosis and Molecular Classification of Lung Cancer;Rodriguez-Canales;Cancer Treat Res,2016
3. Lung Cancer;Herbst;N Engl J Med,2008
4. Clinical Development of Mabs to Block the PD1 Pathway as an Immunotherapy for Cancer;Kline;Curr Opin Investig Drugs (Lond Engl: 2000),2010
5. The Immune Contexture in Human Tumours: Impact on Clinical Outcome;Fridman;Nat Rev Cancer,2012
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献